MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Forma Therapeutics Holdings Inc (NQ: FMTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 13, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 19.98 (496)
Ask (Size) 20.01 (1,384)
Prev. Close 20.01
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 47,852,557
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
Via Benzinga

Performance

More News

Read More
Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease
From Forma Therapeutics, Inc.
Via Business Wire
FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
From Kahn Swick & Foti, LLC
Via Business Wire
4 Analysts Have This to Say About Forma Therapeutics Hldgs
Via Benzinga
Recap: Forma Therapeutics Q2 Earnings
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
Top Russell 2000 Stocks: Trading Opportunities For Next Week - Sunday, Sept. 11
Via Talk Markets
FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2022
Via Benzinga
This Analyst Predicts $700 For Broadcom, Plus RBC Capital Slashes PT On This Stock By 85%
Via Benzinga
Dow Turns Higher; Gold Down 1%
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
Via Benzinga
Nasdaq Tumbles 250 Points; Crude Oil Falls Sharply
Via Benzinga
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout
Via Investor's Business Daily
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
Guardforce AI (GFAI) Stock Gets a Boost From New Exec Team
Via InvestorPlace
Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition News
Via InvestorPlace
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal
Via Benzinga
FMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Forma Therapeutics, Holdings Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
From Forma Therapeutics
Via Business Wire
Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Earnings Scheduled For August 5, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story